Visicol

Constipation, Hypophosphatemia, Parenteral Nutrition, Total + 4 more

Treatment

1 FDA approval

20 Active Studies for Visicol

What is Visicol

Sodium phosphate, dibasic

The Generic name of this drug

Treatment Summary

Sodium phosphate is a type of medication that helps to stimulate a bowel movement by increasing fluid in the small intestine. It usually takes between 30 minutes and 6 hours for the laxative to work.

K Phos Neutral

is the brand name

image of different drug pills on a surface

Visicol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

K Phos Neutral

Sodium phosphate, dibasic

1977

15

Approved as Treatment by the FDA

Sodium phosphate, dibasic, also known as K Phos Neutral, is approved by the FDA for 1 uses which include Parenteral Nutrition, Total .

Parenteral Nutrition, Total

Effectiveness

How Visicol Affects Patients

Sodium phosphate makes stools softer and easier to pass through the large intestine.

How Visicol works in the body

Sodium phosphate is believed to work by adding more substances to the intestines, which causes an imbalance of water in the intestine. This imbalance draws in more water, creating a gradient that helps speed up the intestines.

When to interrupt dosage

The prescribed dosage of Visicol is contingent upon the indicated condition, including fluid and electrolyte upkeep treatment, Fluid substitution therapy and Irrigation. The quantity of dosage is subject to the technique of administration (e.g. Liquid or Tablet, coated) laid out in the table below.

Condition

Dosage

Administration

Hypophosphatemia

, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL

, Intravenous, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Irrigant - Irrigation, Irrigation, Liquid, Topical, Solution - Intravenous, Solution, Tablet, Tablet - Oral, Injection, solution, Solution - Oral, Liquid - Irrigation, Tablet, coated - Oral, Tablet, coated, Injection, solution - Intravenous, Solution - Respiratory (inhalation), Respiratory (inhalation), Rectal, Enema, Injection, Irrigant, Enema - Rectal, Solution - Irrigation, Injection - Intravenous, Powder, Powder - Oral, Kit, Intraocular, Powder, for solution - Intraocular, Kit; Solution, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Spray, Liquid - Buccal, Spray - Buccal, Buccal, Liquid - Topical, Liquid - Oral, Kit; Solution - Intraocular, Powder, for solution

Parenteral Nutrition, Total

, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL

, Intravenous, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Irrigant - Irrigation, Irrigation, Liquid, Topical, Solution - Intravenous, Solution, Tablet, Tablet - Oral, Injection, solution, Solution - Oral, Liquid - Irrigation, Tablet, coated - Oral, Tablet, coated, Injection, solution - Intravenous, Solution - Respiratory (inhalation), Respiratory (inhalation), Rectal, Enema, Injection, Irrigant, Enema - Rectal, Solution - Irrigation, Injection - Intravenous, Powder, Powder - Oral, Kit, Intraocular, Powder, for solution - Intraocular, Kit; Solution, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Spray, Liquid - Buccal, Spray - Buccal, Buccal, Liquid - Topical, Liquid - Oral, Kit; Solution - Intraocular, Powder, for solution

Bowel preparation therapy

, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL

, Intravenous, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Irrigant - Irrigation, Irrigation, Liquid, Topical, Solution - Intravenous, Solution, Tablet, Tablet - Oral, Injection, solution, Solution - Oral, Liquid - Irrigation, Tablet, coated - Oral, Tablet, coated, Injection, solution - Intravenous, Solution - Respiratory (inhalation), Respiratory (inhalation), Rectal, Enema, Injection, Irrigant, Enema - Rectal, Solution - Irrigation, Injection - Intravenous, Powder, Powder - Oral, Kit, Intraocular, Powder, for solution - Intraocular, Kit; Solution, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Spray, Liquid - Buccal, Spray - Buccal, Buccal, Liquid - Topical, Liquid - Oral, Kit; Solution - Intraocular, Powder, for solution

Colonoscopy

, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL

, Intravenous, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Irrigant - Irrigation, Irrigation, Liquid, Topical, Solution - Intravenous, Solution, Tablet, Tablet - Oral, Injection, solution, Solution - Oral, Liquid - Irrigation, Tablet, coated - Oral, Tablet, coated, Injection, solution - Intravenous, Solution - Respiratory (inhalation), Respiratory (inhalation), Rectal, Enema, Injection, Irrigant, Enema - Rectal, Solution - Irrigation, Injection - Intravenous, Powder, Powder - Oral, Kit, Intraocular, Powder, for solution - Intraocular, Kit; Solution, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Spray, Liquid - Buccal, Spray - Buccal, Buccal, Liquid - Topical, Liquid - Oral, Kit; Solution - Intraocular, Powder, for solution

Surgical Procedures

, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL

, Intravenous, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Irrigant - Irrigation, Irrigation, Liquid, Topical, Solution - Intravenous, Solution, Tablet, Tablet - Oral, Injection, solution, Solution - Oral, Liquid - Irrigation, Tablet, coated - Oral, Tablet, coated, Injection, solution - Intravenous, Solution - Respiratory (inhalation), Respiratory (inhalation), Rectal, Enema, Injection, Irrigant, Enema - Rectal, Solution - Irrigation, Injection - Intravenous, Powder, Powder - Oral, Kit, Intraocular, Powder, for solution - Intraocular, Kit; Solution, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Spray, Liquid - Buccal, Spray - Buccal, Buccal, Liquid - Topical, Liquid - Oral, Kit; Solution - Intraocular, Powder, for solution

severe constipation

, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL

, Intravenous, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Irrigant - Irrigation, Irrigation, Liquid, Topical, Solution - Intravenous, Solution, Tablet, Tablet - Oral, Injection, solution, Solution - Oral, Liquid - Irrigation, Tablet, coated - Oral, Tablet, coated, Injection, solution - Intravenous, Solution - Respiratory (inhalation), Respiratory (inhalation), Rectal, Enema, Injection, Irrigant, Enema - Rectal, Solution - Irrigation, Injection - Intravenous, Powder, Powder - Oral, Kit, Intraocular, Powder, for solution - Intraocular, Kit; Solution, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Spray, Liquid - Buccal, Spray - Buccal, Buccal, Liquid - Topical, Liquid - Oral, Kit; Solution - Intraocular, Powder, for solution

Constipation

, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL

, Intravenous, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Irrigant - Irrigation, Irrigation, Liquid, Topical, Solution - Intravenous, Solution, Tablet, Tablet - Oral, Injection, solution, Solution - Oral, Liquid - Irrigation, Tablet, coated - Oral, Tablet, coated, Injection, solution - Intravenous, Solution - Respiratory (inhalation), Respiratory (inhalation), Rectal, Enema, Injection, Irrigant, Enema - Rectal, Solution - Irrigation, Injection - Intravenous, Powder, Powder - Oral, Kit, Intraocular, Powder, for solution - Intraocular, Kit; Solution, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Spray, Liquid - Buccal, Spray - Buccal, Buccal, Liquid - Topical, Liquid - Oral, Kit; Solution - Intraocular, Powder, for solution

Warnings

Visicol has four contraindications and should not be used in coordination with the conditions given in the following table.

There are 20 known major drug interactions with Visicol.

Common Visicol Drug Interactions

Drug Name

Risk Level

Description

Alloin

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Alloin.

Calcium polycarbophil

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Calcium polycarbophil.

Chlorpropamide

Minor

Sodium phosphate, dibasic may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.

Frangula purshiana bark

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Frangula purshiana bark.

Konjac mannan

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Konjac mannan.

Visicol Toxicity & Overdose Risk

Rats have a lethal dose of sodium phosphate of 250mg/kg when given intramuscularly and 8290mg/kg when given orally. High levels of phosphate in the body can cause tetany, dehydration, low blood pressure, rapid heartbeat, extreme fever, and even coma. Smaller patients are more at risk for experiencing phosphate toxicity.

image of a doctor in a lab doing drug, clinical research

Visicol Novel Uses: Which Conditions Have a Clinical Trial Featuring Visicol?

54 active clinical trials are ongoing to investigate the efficacy of Visicol in providing Electrolyte replacement, proctoscopy and Irrigation for treatment of certain conditions.

Condition

Clinical Trials

Trial Phases

severe constipation

0 Actively Recruiting

Bowel preparation therapy

1 Actively Recruiting

Phase 1, Phase 2

Colonoscopy

3 Actively Recruiting

Not Applicable

Constipation

17 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3

Surgical Procedures

0 Actively Recruiting

Hypophosphatemia

1 Actively Recruiting

Phase 2

Parenteral Nutrition, Total

0 Actively Recruiting

Visicol Reviews: What are patients saying about Visicol?

5

Patient Review

1/2/2009

Visicol for Emptying of the Bowel

Easy to use, and the pills went down easily. I was worried about taking so many at once, but it wasn't a problem.

4

Patient Review

11/30/2007

Visicol for Emptying of the Bowel

I experienced an irregular heartbeat and low potassium levels in my blood.

2

Patient Review

3/20/2009

Visicol for Emptying of the Bowel

Unfortunately, this caused me a lot of pain and vomiting. I'm still dealing with the after-effects weeks later.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about visicol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Visicol used for?

"The VISICOL colonoscopy prep medication is only to be used by adults aged 18 and over. It works by causing diarrhea, which in turn cleans out the colon before the procedure. This is important because it allows your doctor to get a better view of the inside of the colon."

Answered by AI

Is Visicol still on the market?

"This product is no longer available under the Visicol name. If the FDA has approved generic versions of this product, there may be generic equivalents available."

Answered by AI

Clinical Trials for Visicol

Have you considered Visicol clinical trials?

We made a collection of clinical trials featuring Visicol, we think they might fit your search criteria.
Go to Trials
Image of Hamilton Health Sciences in Hamilton, Canada.

Kiwifruit Extract for Constipation in Children

4 - 17
All Sexes
Hamilton, Canada

The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation. The main questions it aims to answer are: 1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC? 2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period? Researchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC. Participants will: Undergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups: 1. Actazin chewable tablets (titrate to effect: 600-2400 mg/day) + placebo PEG 3350 2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events. Additionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes. Outcomes: Primary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate. Secondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability. This study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumedi™ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).

Phase 2 & 3
Waitlist Available

Hamilton Health Sciences

Elyanne Ratcliffe, MD

Image of University of Alberta in Edmonton, Canada.

Pelvic Health Rehabilitation for Breast and Gynecologic Cancer

18+
Female
Edmonton, Canada

The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.

Recruiting
Has No Placebo

University of Alberta (+1 Sites)

Have you considered Visicol clinical trials?

We made a collection of clinical trials featuring Visicol, we think they might fit your search criteria.
Go to Trials
Image of Northwestern Memorial Hospital in Chicago, United States.

AI-Assisted Colonoscopy for Polyp Detection

18+
All Sexes
Chicago, IL

Based on prior studies, trainee and practicing gastroenterologists miss pre-cancerous polyps (adenomas and serrated polyps) during colonoscopy. The use of computer-aided detection (CADe) systems, a form of artificial intelligence (AI) has been shown to help identify colorectal lesions for practicing gastroenterologists. However, less is known how AI impacts polyp detection for trainees. The investigators are conducting a tandem colonoscopy study wherein a portion of the colon is examined first by the trainee and then the attending physician. For each procedure, randomization will occur which will determine whether or not the trainee will utilize AI for their examination of the colon. At the end of the study, the investigators will determine whether AI helps trainees miss fewer polyps during colonoscopy. The investigators will also conduct interviews with trainees to understand how AI impacts colonoscopy training.

Recruiting
Has No Placebo

Northwestern Memorial Hospital

Rajesh Keswani, MD

Have you considered Visicol clinical trials?

We made a collection of clinical trials featuring Visicol, we think they might fit your search criteria.
Go to Trials